Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg

In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive…

Read the full article here

Source: UroToday

Categories: General Medicine News, Latest Headlines

Tags: ProstateCancer

Tweets with this article

UroToday.com

Treatment options for metastatic hormone-sensitive #ProstateCancer, advances, and barriers. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss the evolution of prostate cancer care over the last 20 years > https://t.co/e1oU5f3zRv https://t.co/AKOJmk9ZYK

APCCC 2024: Synchronous Low-volume mHSPC – In Which Patients Do You Recommend Combination Systemic Therapy Plus Local Treatment of the Primary and in Which Patients is ADT Alone Plus Radiotherapy Enough?

APCCC 2024 how to manage patients with synchronous low-volume mHSPC, combination systemic therapy plus local treatment of the primary for synchronous low-volume mHSPC, ADT alone…

UroToday.com April 26, 2024

APCCC 2024: Introduction to mHSPC – What Are Relevant Prognostic/Predictive Factors for the Management of Patients?

APCCC 2024 prognostic factors for the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC), predictive factors for the management of patients with mHSPC

UroToday.com April 26, 2024

APCCC 2024: In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis Radiotherapy?

APCCC 2024 treatment for biochemical recurrence/PSA persistence, stereotactic or whole pelvis radiotherapy for patients with biochemical recurrence, APCCC key questions.

UroToday.com April 25, 2024

The Role of Gene Therapy in Enhancing Bladder Cancer Patient Outcomes – Mark Tyson

Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data…

UroToday.com April 25, 2024

APCCC 2024: How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can Be Postponed?

APCCC 2024, Biochemical Relapse, Salvage Radiation Therapy, androgen deprivation therapy (ADT), biochemical recurrence after radical prostatectomy, Oncotype DX, Prolaris, ProMark, Decipher genomic classifier score, utilization…

UroToday.com April 25, 2024

APCCC 2024: Are Some Patients with Biochemical Recurrence (After Radiotherapy And/or Radical Prostatectomy) Candidates for Androgen Receptor Antagonist Monotherapy and How to Manage the Systemic Therapy?

APCCC 2024, prostate cancer, prostate cancer biochemical recurrence, Androgen Receptor Antagonist Monotherapy, EMBARK trial, enzalutamide, bicalutamide, leuprolide acetate, Gynecomastia after prostate cancer treatment, antineoplastic therapy,…

UroToday.com April 25, 2024

APCCC 2024: How to Manage Patients with PSA Persistence Following Radical Prostatectomy?

APCCC 2024 treatment for biochemical recurrence/PSA persistence, Decipher Genomic Classifier, persistent PSA after radical prostatectomy, detectable post-radical prostatectomy PSA.

UroToday.com April 25, 2024

APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Radiation Therapy as Radical Local Treatment (As Part of a Multimodality Approach)

Were you unable to attend APCCC 2024? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.

UroToday.com April 25, 2024

APCCC 2024: High-Risk and Locally Advanced Prostate Cancer in the Context of Current Diagnostic and Therapeutic Options – Which Is the Ideal Definition to Use for Clinical Practice?

APCCC 2024, Prostate Cancer, Ten-year prostate cancer-specific survival rates, CALGB 90203 trial, androgen deprivation therapy (ADT), docetaxel, ADT plus docetaxel, PROTEUS trial, apalutamide, ADT plus…

UroToday.com April 25, 2024

APCCC 2024: Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should Be the Standard?

APCCC 2024, locally advanced prostate cancer, extended pelvic lymph node dissection, radical prostatectomy, pN1 disease, ISUP grade group, PSMA-radio guided techniques.

UroToday.com April 25, 2024

Related Articles